Literature DB >> 16712823

Antigen-specific accumulation of naïve, memory and effector CD4 T cells during anterior uveitis monitored by intravital microscopy.

Per A Dullforce1, Greg W Seitz, Kiera L Garman, Julie A Michael, Sergio M Crespo, Ross J Fleischman, Stephen R Planck, David C Parker, James T Rosenbaum.   

Abstract

Uveitis is an immune-mediated ocular disease and a leading cause of blindness. We characterized a novel model of uveitis with intravital microscopy. Transfer of ovalbumin-specific T cells from DO11.10 spleen to BALB/c recipients and subsequent challenge with ovalbumin in the anterior chamber of the eye resulted in anterior uveitis. Antigen-specificity was verified by injection of irrelevant antigen and transfer of T cells with a different specificity. Subsets of CD4 T cells, including naive (DO11.10 RAG(-/-)) and in vitro-activated Th2 effector CD4 T cells, infiltrated anterior segment tissues early in the inflammation. Memory-like CD44(high) CD4 T cells from unprimed transgenic mice and in vitro-activated Th1 effector CD4 T cells accumulated to larger numbers than naive or Th2 effector cells at 48 and 72 h. Of these, the alpha(2)-integrin+CD4 unprimed T cells entered the eye more efficiently, and antibody to alpha(2)-integrin markedly inhibited the inflammatory response. Intravital microscopy revealed the early arrival and antigen-specific accumulation of CD4 T cells in inflamed tissue and should be helpful in understanding T cell migration to other organs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16712823     DOI: 10.1016/j.cellimm.2006.03.005

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  16 in total

1.  Why HLA-B27? My thirty-year quest: the Friedenwald lecture.

Authors:  James T Rosenbaum
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-29       Impact factor: 4.799

2.  CXCL10 is required to maintain T-cell populations and to control parasite replication during chronic ocular toxoplasmosis.

Authors:  Kazumi Norose; Akitoshi Kikumura; Andrew D Luster; Christopher A Hunter; Tajie H Harris
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-21       Impact factor: 4.799

3.  T cell-antigen-presenting cell interactions visualized in vivo in a model of antigen-specific inflammation.

Authors:  James T Rosenbaum; Mischa B Ronick; Xubo Song; Dongseok Choi; Stephen R Planck
Journal:  Clin Immunol       Date:  2008-03       Impact factor: 3.969

Review 4.  In vivo imaging of the immune response in the eye.

Authors:  Doran B Spencer; Ellen J Lee; Tatsushi Kawaguchi; James T Rosenbaum
Journal:  Semin Immunopathol       Date:  2008-03-05       Impact factor: 9.623

5.  Interferon-γ regulates discordant mechanisms of uveitis versus joint and axial disease in a murine model resembling spondylarthritis.

Authors:  Jelena M Kezic; Michael P Davey; Tibor T Glant; James T Rosenbaum; Holly L Rosenzweig
Journal:  Arthritis Rheum       Date:  2012-03

Review 6.  Biologic agents in experimental autoimmune uveitis.

Authors:  Gian Paolo Giuliari; Ama Sadaka; David M Hinkle
Journal:  Int Ophthalmol       Date:  2013-03-14       Impact factor: 2.031

7.  Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases.

Authors:  Xuebin Liu; Yun Sang Lee; Cheng-Rong Yu; Charles E Egwuagu
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

8.  Ocular regulatory T cells distinguish monophasic from recurrent autoimmune uveitis.

Authors:  Yan Ke; Guomin Jiang; Deming Sun; Henry J Kaplan; Hui Shao
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05-16       Impact factor: 4.799

9.  Reactivation of uveitogenic T cells by retinal astrocytes derived from experimental autoimmune uveitis-prone B10RIII mice.

Authors:  Guomin Jiang; Yan Ke; Deming Sun; Gencheng Han; Henry J Kaplan; Hui Shao
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

10.  Suppression of established experimental autoimmune uveitis by anti-LFA-1alpha Ab.

Authors:  Yan Ke; Deming Sun; Ping Zhang; Guomin Jiang; Henry J Kaplan; Hui Shao
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-06       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.